Bioavailability

Nezglyal remains 'promising' therapy despite EMA’s market authorization refusal

29-Feb-2024 By Isabel Cameron

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently refused marketing authorization for Nezglyal (leriglitazone).

Interview: dsm-firmenich innovates with cannabidiol formulations

28-Nov-2023 By Jonathan Smith

The pharmaceutical and nutritional products specialist dsm-firmenich aims to make better formulations of cannabidiol (CBD).

Legalized medical cannabis five years on - Releaf reveals impact of negative stigma and lack of legal knowledge

27-Nov-2023 By Liza Laws

It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.

Study reveals oil type impacts CBD and THC bioavailability

22-Jun-2023 By Isabel Cameron

New research reveals the bioavailability of both CBD and THC components of hemp, is higher when delivered in certain oil carriers, and describes how some CBD is converted into THC in the body.

Applications of nanotech may provide bioavailability

26-Mar-2019 By Maggie Lynch

Nanotechnology may be able to increase bioavailability in low-solubility drugs and improve a drug’s chance of success, according to Ascendia CEO.

National Research Council of Canada signs cannabinoid biosynthesis agreement

19-Oct-2018 By Maggie Lynch

InMed Pharmaceuticals signed an agreement with the National Research Council of Canada for cannabinoid biofermentation development.